ClinicalTrials.gg
Not yet recruitingNCT07871240Updated Oct 21, 2026

Yijinjing Exercise for Musculoskeletal Health in Adults With Sarcopenia

An interventional study of Modified Yijinjing Exercise and Progressive Resistance Training in Sarcopenia, sponsored by Beijing Hospital of Traditional Chinese Medicine. Not yet recruiting at 6 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Beijing Hospital of Traditional Chinese Medicine · Not applicable, Interventional, and Treatment

Updated Oct 13, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

Sarcopenia is a condition involving loss of muscle mass and strength that can make walking and other daily activities more difficult. This study will compare a modified seven-form Yijinjing exercise program with resistance training in 240 adults aged 50 years or older with sarcopenia at six hospitals in Beijing. Yijinjing is a traditional Chinese exercise that combines movements, breathing and focused attention.

For the first 6 months, participants will be randomly assigned to Yijinjing or resistance training. Exercise is scheduled at least three times per week, with one supervised group session and two remotely supervised home sessions. Both groups will receive the same dietary counseling and health education. The main question is whether Yijinjing improves physical performance at 6 months by an amount that is not meaningfully worse than resistance training. Physical performance will be measured using the Short Physical Performance Battery, which includes balance, walking and repeated chair stands.

After the 6-month assessment, participants in the resistance training group will switch to standard-duration Yijinjing. Eligible participants originally assigned to Yijinjing will be randomly assigned again to standard-duration or longer-duration Yijinjing for another 6 months. Participants who are not eligible for this second random assignment may continue standard-duration Yijinjing when clinically appropriate. Assessments at baseline, 6 months and 12 months will examine muscle mass and strength, physical function, quality of life and other health measures. Exercise-related adverse events will be monitored throughout the 12-month intervention.

Read the detailed description

This multicenter, assessor-blinded study will enroll 240 adults aged 50 years or older with sarcopenia. The two lead centers are Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, and Beijing Jishuitan Hospital, Capital Medical University. Participating centers are Xuanwu Hospital, Capital Medical University; Beijing Friendship Hospital, Capital Medical University; China-Japan Friendship Hospital; and Beijing Luhe Hospital, Capital Medical University. The study is jointly led by principal investigators Yuchao Liu and Wei Tian.

The study uses a two-stage randomized design. During months 0-6, participants are randomized in a 1:1 ratio to modified seven-form Yijinjing or progressive resistance training. The first-stage objective is to evaluate whether Yijinjing is noninferior to resistance training for change in the Short Physical Performance Battery (SPPB) total score from baseline to 6 months. SPPB scores range from 0 to 12, with higher scores indicating better performance. The prespecified noninferiority margin is 0.5 points: noninferiority is concluded if the lower bound of the 95% confidence interval for the between-group difference in change (Yijinjing minus resistance training) exceeds -0.5 points.

Stage 1 Yijinjing sessions last approximately 40-45 minutes, including warm-up and cool-down, three times weekly. Resistance training is performed at least three times weekly for approximately 40 minutes per session and includes five functional exercises for major muscle groups. Weekly delivery consists of one supervised group session and two remotely supervised home sessions. Exercise technique and intensity are adjusted for tolerance and safety.

After the 6-month assessment, all participants originally assigned to resistance training switch to standard-duration Yijinjing for months 7-12. Eligible participants originally assigned to Yijinjing undergo a second 1:1 randomization to standard-duration Yijinjing (40 minutes per session) or extended-duration Yijinjing (progressively increased to 50-60 minutes, with a maximum of 65 minutes including warm-up and cool-down). Both schedules involve three sessions weekly. Original Yijinjing participants who do not meet the prespecified criteria for the second randomization continue standard-duration training if clinically appropriate; they are distinguished from re-randomized participants in analyses. Thus, the three registered treatment pathways arise from the two-stage design rather than an initial three-group randomization. The second stage explores the effects of session duration and longer-term intervention.

All participants receive standardized dietary counseling and health education. Dietary advice targets protein intake of 1.2-1.5 g/kg per day through ordinary food, using the lower of ideal or actual body weight. The study does not supply protein supplements. Health education is delivered weekly during the first three weeks, with identical content and contact time across groups.

Assessments are scheduled at baseline, 6 months and 12 months. In addition to the primary 6-month SPPB endpoint, outcomes include muscle mass index, handgrip strength, walking and chair-stand performance, 12-month SPPB change, quality of life, frailty, cognition, depression and anxiety. Bone mineral density measurements are collected at the two lead centers. Circulating biomarkers are assessed for exploratory mechanistic analyses. Adverse events are monitored throughout the 12-month intervention. Outcome assessors, data managers and primary statistical analysts are blinded to allocation; participants and exercise instructors cannot be blinded.

Enrollment is anticipated to begin in January 2027. Primary outcome collection is expected to finish in September 2028, and 12-month follow-up is expected to finish in March 2029.

02

Conditions studied

  • Sarcopenia

Browse trials for

03

In context

Sarcopenia

1,240 studies on the registry are indexed under Sarcopenia; 405 are open to participants now.

This study's planned enrollment of 240 is above the median of 60 across 793 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Beijing Hospital of Traditional Chinese Medicine is the lead sponsor of 22 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 50 years or older, of either sex.
  • Confirmed sarcopenia with both low muscle mass and low handgrip strength according to the protocol. For ages 50-64: ASMI \<7.6 kg/m² in men or \<5.7 kg/m² in women, and grip strength \<34 kg in men or \<20 kg in women. For ages 65 or older: ASMI \<7.0 kg/m² in men or \<5.7 kg/m² in women, and grip strength \<28 kg in men or \<18 kg in women. ASMI is appendicular skeletal muscle mass measured by multifrequency bioelectrical impedance analysis divided by height squared.
  • Clinically stable, with no acute illness, infection, major surgery or hospitalization within the preceding 4 weeks.
  • Physician assessment confirms ability to tolerate moderate-intensity exercise and safely undertake Yijinjing and resistance training.
  • Adequate cognitive function to cooperate with training, assessments and follow-up.
  • Voluntary written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Severe cardiopulmonary disease, including unstable angina, myocardial infarction within the preceding 3 months, severe heart failure or severe ventilatory impairment.
  • Severe hepatic, renal or endocrine disease, including cirrhosis, renal failure, uncontrolled diabetes or severe thyroid dysfunction.
  • Parkinson disease, residual deficits after stroke, severe joint deformity or persistent back or leg pain preventing completion of the prescribed exercise.
  • Severe cognitive decline, Alzheimer disease, uncontrolled psychiatric illness or severe depression preventing adequate cooperation.
  • Active malignancy or cachexia, or current anticancer treatment.
  • Participation in another sarcopenia intervention trial within the preceding 3 months.
  • Long-term use of glucocorticoids, anabolic hormones or other medicines affecting muscle metabolism.
  • Unstable nutritional status, including weight fluctuation greater than 5% within the preceding month or dependence on parenteral nutrition.
  • Severe osteoporosis with T-score \<= -3.5 or fracture within the preceding 6 months creating a high exercise risk.
  • Other exercise safety concerns or inability to complete study procedures as determined by the investigator.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Yijinjing Followed by Standard-Duration Yijinjing

    Months 0-6: modified seven-form Yijinjing three times weekly, 40-45 minutes per session. Months 7-12: standard-duration Yijinjing, 40 minutes per session, three times weekly. This pathway includes eligible original Yijinjing participants assigned to standard duration by the second randomization, and participants who are not eligible for the second randomization and continue standard duration if clinically appropriate; these subgroups are distinguished in analyses. Weekly delivery consists of one supervised group session and two remotely supervised home sessions. Dietary counseling and health education are provided.

    Behavioral: Modified Yijinjing Exercise · Behavioral: Dietary Counseling and Health Education

  • Experimental
    Yijinjing Followed by Extended-Duration Yijinjing

    Months 0-6: modified seven-form Yijinjing three times weekly, 40-45 minutes per session. After completing the 6-month assessment and meeting the prespecified eligibility criteria, participants assigned to extended duration by the second 1:1 randomization receive modified Yijinjing three times weekly for months 7-12. Session duration increases progressively to 50-60 minutes according to exercise tolerance, with a maximum of 65 minutes including warm-up and cool-down. Weekly delivery consists of one supervised group session and two remotely supervised home sessions. Dietary counseling and health education are provided.

    Behavioral: Modified Yijinjing Exercise · Behavioral: Dietary Counseling and Health Education

  • Active comparator
    Resistance Training Followed by Standard-Duration Yijinjing

    Months 0-6: progressive resistance training at least three times weekly, approximately 40 minutes per session, including warm-up and cool-down. Five exercises are performed for two sets of 6-8 repetitions with 1 minute of rest between sets. Months 7-12: all participants switch to modified seven-form Yijinjing, 40 minutes per session, three times weekly, following technique instruction and a safety assessment. Weekly delivery consists of one supervised group session and two remotely supervised home sessions. Dietary counseling and health education are provided.

    Behavioral: Modified Yijinjing Exercise · Behavioral: Progressive Resistance Training · Behavioral: Dietary Counseling and Health Education

Interventions

  • BehavioralModified Yijinjing Exercise

    Modified seven-form traditional Chinese exercise adapted for adults with sarcopenia, combining movement, breathing and attention. Three sessions weekly: one supervised group session and two remotely supervised home sessions. Stage 1 sessions last 40-45 minutes including warm-up and cool-down; stage 2 standard-duration sessions last 40 minutes and extended-duration sessions progressively increase to 50-60 minutes, maximum 65 minutes. Target Borg RPE is 11-13 on the 6-20 scale. Duration and movement intensity are adjusted for tolerance and safety.

  • BehavioralProgressive Resistance Training

    Six months of progressive resistance training at least three times weekly, approximately 40 minutes per session: 5 minutes of warm-up, 30 minutes of exercise and 5 minutes of cool-down. Five functional exercises target major muscle groups: wall squats, wall push-ups, forward lunges, reverse arm flexion/extension and supported heel raises. Each exercise is performed for two sets of 6-8 repetitions, with 1 minute of rest between sets. One session is supervised in person and two are remotely supervised at home each week. Exercise intensity and technique are adjusted for tolerance and safety. Participants switch to standard-duration modified Yijinjing after the 6-month assessment.

  • BehavioralDietary Counseling and Health Education

    Provided to all treatment pathways. Dietary advice targets total daily protein intake of 1.2-1.5 g/kg through ordinary food, using the lower of ideal or actual body weight. The study does not supply protein supplements. Three-day food diaries, including two weekdays and one non-working day, are reviewed at baseline, 6 months and 12 months with individualized advice. Standardized health education is delivered weekly for the first three weeks, approximately 30 minutes plus 5-10 minutes of questions per session, covering sarcopenia, nutrition, exercise safety and health management. Content and contact time are identical across groups.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Short Physical Performance Battery Total Score at 6 Months

    The Short Physical Performance Battery (SPPB) assesses standing balance, 4-meter walking performance and five repeated chair stands. Total scores range from 0 to 12; higher scores indicate better physical performance. The primary endpoint is the 6-month total score minus the baseline total score. Noninferiority is concluded if the lower bound of the 95% confidence interval for the difference in change (Yijinjing minus resistance training) exceeds -0.5 points.

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Appendicular Skeletal Muscle Mass Index

    Appendicular skeletal muscle mass measured by multifrequency bioelectrical impedance analysis divided by height squared, expressed in kg/m².

    Time frame: Baseline, 6 months and 12 months

  2. Handgrip Strength

    Maximum dominant-hand grip strength from two dynamometer measurements, expressed in kg.

    Time frame: Baseline, 6 months and 12 months

  3. Usual Walking Performance Over 6 Meters

    Time required to walk 6 meters at usual pace, averaged over two trials.

    Time frame: Baseline, 6 months and 12 months

  4. Five-Repetition Chair Stand Performance

    Performance on five repeated chair stands as a measure of lower-limb function.

    Time frame: Baseline, 6 months and 12 months

  5. Change From Baseline in SPPB Total Score at 12 Months

    The 12-month Short Physical Performance Battery total score minus baseline score. Scores range from 0 to 12, with higher scores indicating better physical performance.

    Time frame: Baseline and 12 months

  6. SF-36 Health-Related Quality of Life

    The SF-36 assesses eight domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional health and mental health. Higher scores indicate better health-related quality of life.

    Time frame: Baseline, 6 months and 12 months

  7. Fried Frailty Phenotype

    Frailty is assessed using the Fried Frailty Phenotype, which includes five criteria: unintentional weight loss, slow walking speed, low handgrip strength, low physical activity, and exhaustion. Each criterion is scored as 0 (absent) or 1 (present), yielding a total score ranging from 0 to 5. Higher scores indicate greater frailty and a worse outcome. A score of 0 indicates non-frailty, 1-2 indicates pre-frailty, and 3-5 indicates frailty.

    Time frame: Baseline, 6 months and 12 months.

  8. Montreal Cognitive Assessment

    Cognitive function is assessed using the Montreal Cognitive Assessment. The total score ranges from 0 to 30. Higher scores indicate better cognitive function and a better outcome. When applicable, the education adjustment is applied according to the instrument's scoring instructions, with the adjusted total score capped at 30.

    Time frame: Baseline, 6 months and 12 months

  9. Hamilton Depression Rating Scale

    Depressive symptom severity is assessed using the 24-item Hamilton Depression Rating Scale. The total score is the sum of 24 item scores and ranges from 0 to 76. Higher scores indicate more severe depressive symptoms and a worse outcome.

    Time frame: Baseline, 6 months and 12 months

  10. Hamilton Anxiety Rating Scale

    Anxiety symptom severity is assessed using the 14-item Hamilton Anxiety Rating Scale. Each item is rated from 0 to 4, yielding a total score ranging from 0 to 56. Higher scores indicate more severe anxiety symptoms and a worse outcome.

    Time frame: Baseline, 6 months and 12 months

  11. Adverse Event Incidence

    Adverse events including falls, muscle strains and joint injuries are recorded throughout the intervention, including timing, severity, management and relationship to the intervention.

    Time frame: Throughout the 12-month intervention

  12. Lumbar Spine Bone Mineral Density

    DXA measurement of lumbar spine L1-L4 bone mineral density, collected only for participants enrolled at the two lead institutions.

    Time frame: Baseline, 6 months and 12 months

  13. Femoral Neck Bone Mineral Density

    DXA measurement of femoral neck bone mineral density, collected only for participants enrolled at the two lead institutions.

    Time frame: Baseline, 6 months and 12 months

  14. Total Hip Bone Mineral Density

    DXA measurement of total hip bone mineral density, collected only for participants enrolled at the two lead institutions.

    Time frame: Baseline, 6 months and 12 months

  15. Irisin

    Circulating Irisin measured from morning fasting blood samples for exploratory mechanistic analysis. Sampling is performed at 07:00-09:00 after an 8-12-hour fast, at least 48 hours after the last exercise session and after 20 minutes of seated rest.

    Time frame: Baseline, 6 months and 12 months

  16. Brain-Derived Neurotrophic Factor (BDNF)

    Circulating Brain-Derived Neurotrophic Factor (BDNF) measured from morning fasting blood samples for exploratory mechanistic analysis. Sampling is performed at 07:00-09:00 after an 8-12-hour fast, at least 48 hours after the last exercise session and after 20 minutes of seated rest.

    Time frame: Baseline, 6 months and 12 months

  17. Myostatin

    Circulating Myostatin measured from morning fasting blood samples for exploratory mechanistic analysis. Sampling is performed at 07:00-09:00 after an 8-12-hour fast, at least 48 hours after the last exercise session and after 20 minutes of seated rest.

    Time frame: Baseline, 6 months and 12 months

  18. Follistatin

    Circulating Follistatin measured from morning fasting blood samples for exploratory mechanistic analysis. Sampling is performed at 07:00-09:00 after an 8-12-hour fast, at least 48 hours after the last exercise session and after 20 minutes of seated rest.

    Time frame: Baseline, 6 months and 12 months

  19. Follistatin-to-Myostatin Ratio

    Ratio calculated from measured follistatin and myostatin concentrations as an exploratory mechanistic endpoint.

    Time frame: Baseline, 6 months and 12 months

  20. Insulin-Like Growth Factor 1 (IGF-1)

    Circulating Insulin-Like Growth Factor 1 (IGF-1) measured from morning fasting blood samples for exploratory mechanistic analysis. Sampling is performed at 07:00-09:00 after an 8-12-hour fast, at least 48 hours after the last exercise session and after 20 minutes of seated rest.

    Time frame: Baseline, 6 months and 12 months

  21. Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3)

    Circulating Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) measured from morning fasting blood samples for exploratory mechanistic analysis. Sampling is performed at 07:00-09:00 after an 8-12-hour fast, at least 48 hours after the last exercise session and after 20 minutes of seated rest.

    Time frame: Baseline, 6 months and 12 months

  22. Basal Growth Hormone

    Circulating Basal Growth Hormone measured from morning fasting blood samples for exploratory mechanistic analysis. Sampling is performed at 07:00-09:00 after an 8-12-hour fast, at least 48 hours after the last exercise session and after 20 minutes of seated rest. Single basal growth hormone measurements are used only as an auxiliary indicator because secretion is pulsatile.

    Time frame: Baseline, 6 months and 12 months

  23. Adrenocorticotropic Hormone (ACTH)

    Circulating Adrenocorticotropic Hormone (ACTH) measured from morning fasting blood samples for exploratory mechanistic analysis. Sampling is performed at 07:00-09:00 after an 8-12-hour fast, at least 48 hours after the last exercise session and after 20 minutes of seated rest.

    Time frame: Baseline, 6 months and 12 months

  24. Cortisol

    Circulating Cortisol measured from morning fasting blood samples for exploratory mechanistic analysis. Sampling is performed at 07:00-09:00 after an 8-12-hour fast, at least 48 hours after the last exercise session and after 20 minutes of seated rest.

    Time frame: Baseline, 6 months and 12 months

07

Study locations

6 sites
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
  • Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
    Beijing, Beijing Municipality, China
  • Beijing Jishuitan Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
  • Beijing Luhe Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality, China
  • Xuanwu Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

2 registry updates since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 2 updates
  1. Oct 21, 2026
    Minor edits only
    + 1 other change: secondary outcomes
  2. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07871240
Lead sponsor
Beijing Hospital of Traditional Chinese Medicine
Responsible party
Yuchao Liu (Investigator, Beijing Hospital of Traditional Chinese Medicine) — Principal investigator
First posted
Oct 13, 2026
Start date
Jan 2027 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

Yuchao Liu
Contact
lych74@126.com
+86 13716303080
Yuchao Liu
principal investigator · Beijing Hospital of Traditional Chinese Medicine
Wei Tian
principal investigator · Beijing Jishuitan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion